Why Is Miro Sciences (ASX:MSX) Stock Up Today?

Sonal Goyal

05 November 2026 01:00 PM AEDT

Why Is Miro Sciences (ASX:MSX) Stock Up Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Miro Sciences shares were priced at $0.051 during the 5 November 2026 trading session, up 13.33%.
The company's investor presentation, dated November 2026, focuses on its StemSmart program for severe Crohn's disease.
The presentation states the company was formerly known as NeuroScientific Biopharmaceuticals (ASX:NSB).

Miro Sciences Ltd (ASX:MSX) shares were priced at $0.051 during the Trading session on 5 November 2026, up 13.33%. The S&P/ASX 200 was up 1.88%, or 166.10 points, at 9,000.60 at around 12:15 pm Sydney time, so the broader market was also trading higher during the session. Miro Sciences is a biopharmaceutical company advancing its StemSmart therapy towards a potential treatment for severe Crohn's disease. The latest material is an investor presentation dated November 2026, which the company has made available to the market.

Latest Development: Investor Presentation (November 2026)

The company's November 2026 presentation sets out its StemSmart program and describes progress towards a new treatment for severe Crohn's disease. The presentation notes that it was prepared on information available at the Date of Issue and includes forward-looking statements, which carry risks and uncertainties.

The presentation is a summary document and does not contain all of the information investors would need to make a decision, so readers are referred to the company's full ASX announcements for detail.

Sector Context

The health care sector was up 2.86% in the session, a broad move that sits alongside the company's own news flow. Clinical-stage biopharmaceutical companies are often assessed against trial timelines and regulatory milestones, which can take years to reach.

What to Watch Ahead

Investors may track the next clinical and regulatory updates for StemSmart and any further company presentations.

Key Risks

Clinical development carries significant risk, and results may not support approval. Funding requirements can be substantial. The presentation itself warns that forward-looking statements may differ materially from actual results.

Final Word

Miro Sciences shares rose in the session, and the company's latest presentation covers its StemSmart development. Future clinical and regulatory announcements will set out the program's next stages.

FAQs

Q: How did Miro Sciences shares trade on 5 November 2026?

A: MSX shares were priced at $0.051 during the trading session, up 13.33%, while the S&P/ASX 200 was also trading higher.

Q: What is StemSmart?

A: StemSmart is the company's program, which the presentation describes as advancing towards a new treatment for severe Crohn's disease.

Q: Is the presentation a financial statement?

A: No. The company says the presentation is a summary and does not contain all the information needed to make an investment decision.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.